PillCarboplatin
Carboplatin
8 active makers
soon
soon
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it8 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Teva Parenteral Medicines, Inc. | unknown | 8 | SUPPLYING |
| Hospira, Inc. | unknown | 8 | SUPPLYING |
| Eugia US LLC | unknown | 6 | SUPPLYING |
| Apotex Corp. | unknown | 4 | SUPPLYING |
| Gland Pharma Limited | unknown | 4 | SUPPLYING |
| Teyro Labs Private Limited | unknown | 4 | SUPPLYING |
| BPI Labs LLC | unknown | 4 | SUPPLYING |
| Fresenius Kabi USA, LLC | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Fresenius Kabi USA, LLC)
Carboplatin Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Oncology.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Eugia US LLC)
Carboplatin Injection — reported in shortage by Eugia US LLC. Therapeutic category: Oncology.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Teyro Labs)
Carboplatin Injection — reported in shortage by Teyro Labs. Therapeutic category: Oncology.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Teva Pharmaceuticals USA, Inc.)
Carboplatin Injection — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Oncology.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Gland Pharma Limited)
Carboplatin Injection — reported in shortage by Gland Pharma Limited. Therapeutic category: Oncology.
- Apr 28, 2023SHORTAGEDrug shortage: Carboplatin Injection (Hospira, Inc., a Pfizer Company)
Carboplatin Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Oncology.
- Nov 8, 2012RECALLRecall (Class I): Carboplatin Injection, 600 mg/60 mL (10 mg/mL), 60 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, …
Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals. — Recalling firm: Hospira Inc. — Nationwide and Puerto Rico.
- Nov 8, 2012RECALLRecall (Class I): Carboplatin Injection, 450 mg/45 mL (10 mg/mL), 45 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, …
Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals. — Recalling firm: Hospira Inc. — Nationwide and Puerto Rico.
- Jul 2, 2012RECALLRecall (Class III): Carboplatin Injection, 10 mg/mL, a) 5 mL multi-dose vials (NDC 61703-339-18) (NDC 61703-360-18, NOVAPLUS), b) 45 mL mu…
Failed PH specification: The lots of Carboplatin Injection were manufactured from Carboplatin API lots which trended out of specification low pH. — Recalling firm: Hospira Inc. — Nationwide and Puerto Rico
- Jun 27, 2012RECALLRecall (Class II): Carboplatin Injection, 10 mg/mL, 45 mL Multi-Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hosp…
The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are beig recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution. — Recalling firm: Hospira Inc. — Nationwide, including Puerto Rico and Guam. Product was also distributed internationally to Australia, Belgium, Cana…